Theriva Biologics announces sale of Syn-004 and related enzyme portfolio to Biossil Labs
TOVX•Theriva Biologics announced the sale of Syn-004 (ribaxamase) and its related antibiotic-degrading enzyme portfolio to Biossil Labs Inc.
1. Portfolio sale
Theriva Biologics announced the sale of Syn-004 (ribaxamase) and its related antibiotic-degrading enzyme portfolio to Biossil Labs Inc.
